Reviewing Beta Bionics and Coloplast A/S

Two medical companies, but which is the better investment?

Published on Feb. 15, 2026

Got story updates? Submit your updates here. ›

Beta Bionics (NASDAQ:BBNX) and Coloplast A/S (OTCMKTS:CLPBY) are both medical companies, but a comparison of the two reveals which may be the better investment option based on factors like valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, and dividends.

Why it matters

Investors looking to diversify their portfolios with medical technology stocks will want to understand the relative strengths and weaknesses of these two companies to make an informed decision about which one may be the better long-term investment.

The details

The analysis shows that Beta Bionics has a stronger consensus rating from analysts and a higher potential upside, while Coloplast A/S has higher revenue and earnings. Beta Bionics also trades at a lower price-to-earnings ratio, indicating it may be more affordable. However, Coloplast A/S outperforms Beta Bionics on several key financial metrics like net margins, return on equity, and return on assets.

  • The analysis is based on recent ratings and target prices reported by MarketBeat.com.

The players

Beta Bionics

A commercial-stage medical device company that designs, develops, and commercializes solutions for insulin-requiring people with diabetes.

Coloplast A/S

A Danish company that develops and sells intimate healthcare products and services, including ostomy care, continence care, wound care, and surgical products for urological and gynecological disorders.

Got photos? Submit your photos here. ›

The takeaway

Investors will need to weigh the relative strengths and weaknesses of Beta Bionics and Coloplast A/S to determine which company may be the better long-term investment option based on their individual investment goals and risk tolerance.